From Generics to Strategic Capability: Why India’s Pharma Success Is Running Into an Upstream Wall
India remains one of the world’s most important suppliers of affordable medicines. But a business model built on imported chemistry, thin upstream depth and uneven research capacity is now colliding with a harder policy question: can India stay the “pharmacy of the world” without rebuilding the science, manufacturing and regulatory plumbing underneath it?